Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 25;11(12):594.
doi: 10.3390/vetsci11120594.

Echocardiographic Changes in Dogs with Stage B2 Myxomatous Mitral Valve Disease Treated with Pimobendan Monotherapy

Affiliations

Echocardiographic Changes in Dogs with Stage B2 Myxomatous Mitral Valve Disease Treated with Pimobendan Monotherapy

Andrew Crosland et al. Vet Sci. .

Abstract

The present study aimed to evaluate the effects of chronic pimobendan monotherapy on cardiac size in dogs with stage B2 myxomatous mitral valve disease (MMVD). Data from 31 dogs diagnosed with MMVD and cardiomegaly (LA/Ao ≥ 1.6 and LVIDdn ≥ 1.7) were included. The intervention group were dogs treated with pimobendan (n = 24). Dogs not receiving any cardiac medication were controls (n = 7). Echocardiographic changes in left atrial and left ventricular dimensions were compared over time. There was significant group × time interaction for LVIDdN (p = 0.011) between diagnosis and initial follow-up (median 3-6 months). There was a significant reduction in LVIDdN over time in the pimobendan group (p = 0.038) but not in the control group (p = 0.216). There was no significant group × time interaction for LA/Ao, and there was no effect of group (p = 0.561), but LA/Ao in both groups decreased over time (p = 0.01). Restraint is advised when prescribing pimobendan based on the detection of a heart murmur where echocardiographic staging is an option. Some stage B2 dogs that received pimobendan no longer met the echocardiographic classification criteria for stage B2 MMVD and could have been misclassified as stage B1 and had their medication inappropriately withdrawn. We suggest these dogs are referred to as reverse remodelled stage B2.

Keywords: canine; degenerative mitral valve disease; pimobendan; reverse remodelling.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
(a) Box and whisker plot demonstrating the distribution of LVIDdN across the pimobendan group and control group at the time of enrollment (Time 0) and at first recheck (Time 1). Boxes represent the interquartile range, with the median indicated with the line dividing the box. Outliers are represented by solid dots. (b) Box and whisker plot demonstrating the distribution of LA/Ao across the pimobendan group and control group at the time of enrollment (Time 0) and at first recheck (Time 1). Boxes represent the interquartile range, with the median indicated with the line dividing the box. Outliers are represented by solid dots.

References

    1. Borgarelli M., Haggstrom J. Canine degenerative myxomatous mitral valve disease: Natural history, clinical presentation and therapy. Vet. Clin. N. Am. Small Anim. Pract. 2010;40:651–663. doi: 10.1016/j.cvsm.2010.03.008. - DOI - PubMed
    1. Detweiler D.K., Patterson D.F. The prevalence and types of cardiovascular disease in dogs. Ann. N. Y. Acad. Sci. 1965;127:481–516. doi: 10.1111/j.1749-6632.1965.tb49421.x. - DOI - PubMed
    1. Keene B.W., Atkins C.E., Bonagura J.D., Fox P.R., Haggstrom J., Fuentes V.L., Oyama M.A., Rush J.E., Stepien R., Uechi M. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J. Vet. Intern. Med. 2019;33:1127–1140. doi: 10.1111/jvim.15488. - DOI - PMC - PubMed
    1. Boswood A., Haggstrom J., Gordon S.G., Wess G., Stepien R.L., Oyama M.A., Keene B.W., Bonagura J., MacDonald K.A., Patteson M., et al. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. J. Vet. Intern. Med. 2016;30:1765–1779. doi: 10.1111/jvim.14586. - DOI - PMC - PubMed
    1. Cornell C.C., Kittleson M.D., Della Torre P., Haggstrom J., Lombard C.W., Pedersen H.D., Vollmar A., Wey A. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J. Vet. Intern. Med. 2004;18:311–321. doi: 10.1892/0891-6640(2004)18<311:asomcm>2.0.co;2. - DOI - PubMed

LinkOut - more resources